NAVIGATING THE METABOLIC PATHWAYS OF MEFTAL: IMPLICATIONS FOR WOMEN'S WELL-BEING

Divneet Kaur, Prachi sharma, Rekha Rana*
School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab

ABSTRACT

Introduction: This comprehensive analysis explores the background and significance of Meftal, a nonsteroidal anti-inflammatory drug (NSAID), amidst recent safety concerns related to DRESS syndrome. The objective is to provide an in-depth understanding of Meftal's mechanisms of action, metabolism, and associated risks to guide future research and clinical practice. **Methods:** The analysis incorporates a review of existing literature, drug safety alerts, and clinical data pertaining to Meftal. Emphasis is placed on elucidating its metabolism in healthy individuals, covering aspects such as absorption, distribution, liver biotransformation, and excretion pathways. Additionally, the analysis delves into pharmacokinetic and pharmacodynamic variability and explores metabolic alterations induced by Meftal in various disease states. **Results:** The analysis reveals the diverse spectrum of side effects and complications associated with Meftal, including skin rashes, metabolic acidosis, thrombotic thrombocytopenic purpura, and acute pancreatitis. It highlights the importance of monitoring and reporting adverse reactions in response to recent safety alerts issued by regulatory authorities. Moreover, the variability in Meftal's metabolism and its impact on efficacy and safety profiles are discussed, along with hidden risks such as cardiovascular effects, gastrointestinal complications, and nephrotoxicity. **Conclusion:** This analysis provides a comprehensive understanding of Meftal's metabolism and associated risks, emphasizing the need for vigilant monitoring and reporting of adverse reactions. Future research directions, emerging trends, and potential therapeutic innovations are discussed to address existing research gaps and challenges in Meftal's clinical use. Ultimately, the aim is to inform clinical practice and guide the development of safer and more effective therapeutic strategies involving Meftal.

Keywords: Meftal, Nonsteroidal Anti-Inflammatory Drug (NSAID), Metabolism, Adverse Reactions, Pharmacokinetics and Pharmacodynamics



Graphical Abstract: Meftal's Potent Relief and Cautionary Tales

1. INTRODUCTION

1.1 Meftal and its common use as a nonsteroidal anti-inflammatory drug (NSAID)

Meftal chemically known as Mefenamic Acid, is a nonsteroidal anti-inflammatory drug (NSAID) that belongs to the fenamate class [1]. It's recognized by its chemical structure C15H15NO2. The drug operates by inhibiting the cyclooxygenase (COX) enzyme which in turn reduces the production of prostaglandins which are the compounds responsible for causing pain and inflammation. This mechanism makes Meftal an effective remedy for various types of pain, including headaches, migraines, nerve pain, toothaches, menstrual pains, arthritis, and muscle aches. It's also utilized for the treatment of mild to moderate visceral pains and different inflammatory conditions associated with pain and fevers [2, 3]. However, in India, the use of Meftal has been closely monitored due to potential adverse reactions. In December 2023, the Indian Pharmacopoeia Commission (IPC) issued a safety alert due to the risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome associated with Meftal. DRESS syndrome is a severe allergic reaction that can be life-threatening. Therefore, healthcare professionals and patients are advised to be vigilant for signs of DRESS syndrome and other adverse drug reactions [4]. Any such symptoms should be promptly reported to the national coordination center of the Pharmacovigilance Programme of India (PvPI).

1.2 Recent association with DRESS syndrome and the drug safety alert issued by the IPC

A drug safety alert issued by the Indian Pharmacopoeia Commission (IPC) for the painkiller Meftal. The alert warns that Meftal which contains mefenamic acid, a non-steroidal anti-inflammatory drug (NSAID), can cause severe allergic reactions known as DRESS syndrome. DRESS's syndrome is a rare but potentially life-threatening condition that manifests as skin rash, fever, hematological abnormalities, internal organ involvement, and lymphadenopathy, two to eight weeks after drug intake [5]. Meftal-Spas is commonly prescribed for various conditions such as arthritis, dysmenorrhoea, pain, inflammation, fever, and dental pain. However, it can also cause side effects such as abdominal pain, indigestion, dry mouth, blurred vision, increased blood pressure, swelling, skin rash, gastrointestinal issues, fertility problems, kidney problems, and cardiovascular events. The IPC's alert serves as a reminder of the potential risks associated with the overuse of painkillers and the need for responsible medication practices. Patients are advised to consult healthcare providers before starting or continuing treatment with Meftal-Spas and to report any adverse drug reactions to the PvPI.

1.3 Structure of mefenamic acid

Mefenamic acid, a distinguished member of the fenamate class which is a chemical compound derived from anthranilic acid exhibiting intriguing conformational properties [6]. The molecular formula of mefenamic acid is C15H15NO2, and its systematic name is 2-[(2,3-dimethylphenyl) amino] benzoic acid which is the backbone of mefenamic acid features an anthranilic acid derivative where a benzene ring is adorned with an amino group (NH2) and a carboxylic acid group (COOH) as shown in figure 1. A notable modification involves the substitution of one of the hydrogen atoms attached to the nitrogen atom with a 2,3-dimethylphenyl fragment. This alteration imparts a distinctive character to the molecule, contributing to its pharmacological activities [7].

The 2,3-dimethylphenyl fragment adds a layer of intricacy to mefenamic acid's structure. The benzene ring within this fragment introduces methyl groups at positions 2 and 3 creating a symmetrical yet asymmetrically substituted aromatic system. The presence of the amino and carboxylic acid groups on the anthranilic acid moiety in conjunction with the substituted phenyl fragment endows mefenamic acid with the ability to modulate biochemical pathways crucial in inflammation and pain response [8].



Figure Structure of Mefenamic acid

1.4 Various side effects and complications linked to Meftal

Meftal can also have several side effects and complications that can affect different parts of the body. Some of the

common side effects of Meftal are diarrhea, constipation, gas, bloating, headache, dizziness, nervousness, and ringing in the ears [9]. These side effects are usually mild and temporary but they can become severe or persistent in some cases. Meftal can also cause stomach problems such as abdominal pain, indigestion, dry mouth, ulcers, bleeding, and perforation. These problems can be serious and life-threatening, especially if Meftal is taken for a long time or in high doses. Meftal can also affect vision and cause blurred vision or eye irritation4. Meftal can also increase the blood pressure and cause swelling or fluid retention in some people. This can increase the risk of heart problems such as heart attack or stroke [10, 11]. Meftal can also affect the kidneys and cause kidney problems such as reduced urine output, blood in urine, or kidney failure. These problems can be irreversible and require dialysis or transplantation. Meftal can also cause allergic reactions in some people who are sensitive to mefenamic acid or other NSAIDs [12]. These reactions can range from mild skin rashes to severe anaphylaxis. One of the rare but serious allergic reactions that Meftal can cause is DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome. This is a condition that occurs two to eight weeks after taking Meftal and causes symptoms such as skin rash, fever, swollen lymph nodes, blood abnormalities, and internal organ damage. DRESS syndrome can be fatal if not treated promptly [13].

2. BACKGROUND AND SIGNIFICANCE

2.1 Meftal's historical use and significance in pain and inflammation management

Meftal was first introduced in the UK in 1963 developed by Parke-Davis and has been widely used in many countries since then. In the early years, Meftal gained recognition for its efficacy in alleviating pain associated with various conditions particularly menstrual pain. The drug's ability to provide relief from dysmenorrhea contributed to its widespread acceptance and adoption in gynecological practice [14, 15]. The menstrual pain relief properties of Meftal were especially significant in improving the quality of life for many women. Over the decades, Meftal's use expanded beyond menstrual pain to include the management of musculoskeletal disorders, inflammatory conditions, and other pain-related ailments [16, 17]. Its versatility in addressing different types of pain made it a preferred choice for healthcare professionals in diverse clinical settings. The historical context of Meftal's use also reflects a continuous effort to refine and optimize NSAID therapy. As with any medication, the evolution of Meftal involves ongoing research and development to enhance its safety and efficacy profile. This historical perspective serves as a backdrop to the current challenges and concerns associated with Meftal, such as its recent association with DRESS syndrome and other adverse reactions.

2.2 Importance of understanding its side effects and complications in clinical practice

In clinical practice, a nuanced understanding of the side effects and complications associated with Meftal is essential for ensuring patient safety and making informed treatment decisions. Healthcare professionals must conduct a thorough risk-benefit assessment considering individual patient factors and susceptibilities to potential complications. Early recognition of adverse reactions enables prompt intervention, mitigating the severity of complications and improving patient outcomes. This knowledge also guides the choice of NSAIDs helping clinicians select the most appropriate medication for individual patients based on their health status and medical history. Educating patients about Meftal's side effect profile fosters adherence to medication regimens while regular monitoring allows for the timely detection of emerging complications. Moreover, understanding Meftal's side effect profile contributes to public health surveillance providing valuable insights into the overall safety of the drug. In navigating the delicate balance between therapeutic benefits and potential risks, healthcare professionals uphold legal and ethical standards, ensuring responsible and patient-centered care.

3. MECHANISM OF ACTION

As a member of the nonsteroidal anti-inflammatory drug (NSAID) class, mefenamic acid targets both COX-1 and COX-2 pivotal enzymes involved in the arachidonic acid metabolic pathway. COX-1 is constitutively expressed in various tissues and is responsible for maintaining physiological functions such as gastric mucosal integrity and platelet aggregation. In contrast, COX-2 is an inducible enzyme primarily associated with the production of prostaglandins during inflammatory responses. Mefenamic

acid's non-selective inhibition of both COX isoforms interferes with the conversion of arachidonic acid into prostaglandins notably prostaglandin H2 [18, 19]. Prostaglandins play a crucial role as lipid signaling molecules contributing to the initiation and propagation of inflammatory responses, pain perception, and fever. The inhibition of prostaglandin synthesis by mefenamic acid translates into a multifaceted anti-inflammatory effect. Firstly, the drug curtails vasodilation reducing the diameter of blood vessels and consequently mitigating the redness and swelling characteristic of inflammation [20]. Secondly, mefenamic acid attenuates increased vascular permeability reducing the leakage of fluid into surrounding tissues and further alleviating swelling. Additionally, by suppressing prostaglandin production, mefenamic acid modulates the immune response, influencing the activation and migration of immune cells to sites of inflammation. Furthermore, mefenamic acid exhibits analgesic properties, providing relief from pain, and antipyretic effects, reducing fever. These combined effects make mefenamic acid a versatile choice in managing a spectrum of conditions characterized by inflammation and pain ranging from musculoskeletal disorders to menstrual cramps. However, the non-selective nature of mefenamic acid's COX inhibition warrants careful consideration of potential side effects particularly those related to gastrointestinal mucosal integrity. The delicate balance between the therapeutic benefits of mefenamic acid and the risk of adverse reactions underscores the importance of individualized treatment plans and vigilant monitoring in clinical practice [21-23].

4. A DETAILED ANALYSIS OF MEFTAL'S METABOLISM IN HEALTHY INDIVIDUALS

In healthy individuals, the metabolism of Meftal (mefenamic acid) unfolds through a series of intricate processes, illuminating the drug's pharmacokinetic profile. Following oral administration, Meftal undergoes absorption primarily in the gastrointestinal tract, reaching peak plasma concentrations within hours. This absorption can be influenced by food intake, impacting the drug's bioavailability. Once in the bloodstream, Meftal exhibits moderate protein binding, notably to albumin, facilitating its distribution to various tissues, including those affected by inflammation. The liver assumes a pivotal role in Meftal's metabolism, where it undergoes hepatic biotransformation predominantly mediated by cytochrome P450 enzymes, particularly CYP2C9 [2, 24]. This process results in the formation of pharmacologically active metabolites, including 3'-hydroxymethyl mefenamic acid. Renal excretion then plays a crucial role in eliminating Meftal and its metabolites from the body. Variability in pharmacokinetics may arise from factors such as age, genetic polymorphisms, and drug interactions, necessitating careful consideration in clinical practice (24). A comprehensive understanding of Meftal's metabolism in healthy individuals lays the foundation for personalized dosing strategies ensuring both efficacy and safety in the management of pain and inflammation.

4.1 Absorption

Mefenamic acid, the principal active component of Meftal, undergoes a sophisticated and multi-faceted process of absorption when administered orally. Delivered in the form of tablets or capsules, mefenamic acid navigates the intricacies of the gastrointestinal tract to facilitate its entry into the systemic circulation [25]. Absorption takes place not only from the stomach but also prominently from the small intestine, a phenomenon influenced by various factors. The drug's solubility and dissolution characteristics are pivotal; being a weak acid with limited water solubility, the extent of its dissolution in the aqueous milieu of the gastrointestinal tract significantly impacts its absorption kinetics [26]. The pH-dependent nature of mefenamic acid absorption is noteworthy, with optimal uptake occurring in the more alkaline environment of the small intestine. Importantly, the presence of food in the stomach can exert a profound influence on the drug's absorption dynamics. While it may slow down the absorption rate, it simultaneously enhances the overall bioavailability of mefenamic acid [27]. This intricate interplay of factors underscores the importance of considering the timing of administration concerning food intake for optimal therapeutic outcomes. Individual variability in absorption, influenced by patient-specific physiological characteristics, concurrent medications, and the presence of gastrointestinal conditions, further adds complexity to the drug's bioavailability. These insights into mefenamic acid's absorption kinetics are paramount for healthcare practitioners, guiding them in tailoring precise dosing regimens and optimizing therapeutic strategies for the

effective and safe management of pain and inflammation in diverse clinical scenarios [28].

4.2 Distribution

Mefenamic acid is the active ingredient in Meftal which embarks on a complex journey of distribution once it is absorbed into the bloodstream. A critical determinant in this process is the drug's interaction with plasma proteins particularly its moderate binding affinity to albumin [29]. This protein binding intricately shapes the distribution of mefenamic acid within the bloodstream and influences its ability to traverse various tissues. Tissue perfusion rates, reflective of the blood flow to different organs play a pivotal role in determining the drug's distribution pattern. In well-vascularized tissues, higher perfusion rates facilitate an increased delivery of mefenamic acid, a characteristic that holds significance in the context of managing inflammatory conditions where tissues may exhibit altered blood flow. Moreover, the drug's distribution is not uniform, and its penetration into inflamed tissues is notably influenced by the presence of inflammation. Inflammatory processes can modify local blood flow and vascular permeability, potentially enhancing mefenamic acid's access to and efficacy in inflamed tissues. The competition for protein binding sites in the presence of other drugs can also impact the distribution of mefenamic acid, altering its free (unbound) fraction in the bloodstream. Additionally, mefenamic acid has demonstrated the ability to cross the blood-brain barrier to some extent, exerting effects on the central nervous system and contributing to its analgesic and antipyretic actions. The variability in distribution among individuals may arise from genetic variations, age-related factors, and the presence of coexisting medical conditions, influencing the drug's concentration at target sites. Understanding the intricate dynamics of mefenamic acid's distribution is paramount for clinicians, guiding them in tailoring precise dosing regimens and optimizing therapeutic strategies to ensure effective and targeted management of pain and inflammation in diverse clinical scenarios [30].

4.3 Liver biotransformation

The hepatic biotransformation of mefenamic acid which is the active component of Meftal unfolds as a sophisticated and intricate process within the liver, elucidating critical aspects of its pharmacokinetics. At the forefront of this metabolic transformation are the cytochrome P450 enzymes, notably CYP2C9 which play a central role in initiating oxidation reactions that lead to the formation of metabolites. The principal metabolite generated through this process is 3'-hydroxymethyl mefenamic acid, a compound that retains pharmacological activity and contributes significantly to the therapeutic effects of the drug. Complementary conjugation reactions, such as glucuronidation, further modify the drug and its metabolites, facilitating their excretion [31]. Mefenamic acid undergoes oxidation reactions, primarily hydroxylation, at various positions, contributing to the diverse metabolic pathways the drug undergoes within the hepatic environment. This intricate interplay of enzymatic reactions ultimately yields water-soluble compounds that can be readily eliminated from the body. Importantly, the biotransformation of mefenamic acid is subject to individual variability influenced by genetic polymorphisms in enzymes like CYP2C9 [32]. This variability may lead to differences in the rate and extent of drug metabolism among individuals, influencing overall pharmacokinetics. Additionally, the involvement of CYP2C9 in mefenamic acid metabolism has implications for potential drug interactions, as co-administration of drugs that modulate CYP2C9 activity may alter the drug's metabolic fate. The renal excretion of metabolites, including the pharmacologically active 3'-hydroxymethyl mefenamic acid, further completes the intricate process, underscoring the importance of understanding the hepatic biotransformation of mefenamic acid. This comprehensive knowledge not only provides insights into the drug's metabolism but also guides clinical decision-making, enabling tailored dosing strategies, predicting potential drug interactions, and ensuring the safe and effective use of mefenamic acid in diverse patient populations [2].

4.4 Excretion

The excretion pathway of mefenamic acid, a fundamental aspect of its pharmacokinetics, primarily involves renal elimination, showcasing an intricate interplay of processes that contribute to the drug's efficient removal from the body. Renal excretion stands as the cornerstone of this elimination, playing a central role in clearing both the parent drug and its metabolites. Although a fraction of mefenamic acid may be

excreted unchanged in the urine, the majority undergoes hepatic biotransformation, yielding water-soluble metabolites such as the pharmacologically active 3'-hydroxymethyl mefenamic acid. The hydrophilic nature of these metabolites, facilitated by processes like glucuronidation, enhances their water solubility, ensuring their effective elimination through the kidneys. The efficiency of renal excretion is reflected in the drug's relatively short elimination half-life, ranging from 2 to 4 hours, signifying the rapid clearance of mefenamic acid from the systemic circulation. The urinary route emerges as the primary channel for excretion, with metabolites filtered by the renal glomeruli and subsequently excreted into the urine. Individual variability in renal function, age-related changes, and the presence of renal impairment can influence mefenamic acid's excretion dynamics [33]. Additionally, the potential impact of drug interactions on renal function underscores the importance of considering these factors in clinical practice. In sum, comprehending the intricacies of mefenamic acid's renal excretion pathway not only provides insights into its clearance mechanisms but also guides clinicians in optimizing dosing regimens and anticipating potential influences on the drug's elimination kinetics in diverse patient populations.

5. VARIABILITY IN PHARMACOKINETICS AND PHARMACODYNAMICS

5.1 Individual variability

Individual variability in the response to Meftal encompassing a spectrum of factors such as age, genetic diversity, and underlying health conditions significantly influences the drug's efficacy and safety profile. Age-related differences play a pivotal role with pediatric and elderly populations exhibiting distinct metabolic characteristics that impact drug processing. Genetic polymorphisms, particularly in genes governing the metabolism of Meftal, introduce variability in drug clearance, with specific variants influencing individual responses. Concurrent health conditions, especially hepatic or renal impairment, can alter drug metabolism and clearance, accentuating the need for personalized treatment considerations. Concomitant medications may interact with Meftal, affecting its pharmacokinetics and dynamics. Lifestyle factors, cultural disparities, and hormonal influences contribute to the intricate web of individual variability. Acknowledging these factors is paramount for clinicians, facilitating the tailoring of treatment regimens to optimize therapeutic benefits while minimizing potential risks for each unique patient. This personalized approach, coupled with vigilant monitoring and open communication, ensures a comprehensive strategy for managing individual variability in Meftal response [34].

5.2 Genetic polymorphisms

Genetic polymorphisms, specifically within the cytochrome P450 2C9 (CYP2C9) gene, exert a profound influence on the response to Meftal, a nonsteroidal anti-inflammatory drug containing mefenamic acid. The presence of allelic variants, notably CYP2C9*2 and CYP2C9*3, introduces variability in enzymatic activity, impacting the metabolism of Meftal in the liver. Individuals carrying these polymorphisms may experience altered drug clearance, leading to variations in systemic exposure. Poor metabolizers, characterized by reduced CYP2C9 activity, may face an increased risk of adverse events due to prolonged drug half-life. Conversely, extensive metabolizers may clear the drug more rapidly, potentially affecting its overall efficacy. The clinical implications of these genetic polymorphisms are profound, necessitating personalized dosing regimens based on individual pharmacogenetic profiles. Pharmacogenetic testing becomes a valuable tool in identifying specific genotypes, guiding clinicians in tailoring Meftal therapy to optimize benefits and minimize risks. Considering the population variability in the prevalence of these polymorphisms among different ethnic groups further underscores the importance of genetic diversity in informing global treatment decisions. Ongoing research in pharmacogenomics holds promise for uncovering additional genetic factors, paving the way for a more nuanced and precise approach to Meftal therapy in diverse patient populations [35, 36].

5.3 Pharmacokinetic variability

Pharmacokinetic variability in Meftal response encompasses the dynamic interplay of factors governing the absorption, distribution, metabolism, and excretion (ADME) processes within the body. The absorption of Meftal is influenced by variables such as gastrointestinal health, food intake, and specific drug formulations, introducing variability in the rate and extent of drug absorption. Distribution, determined by

individual differences in body composition, tissue perfusion, and protein binding capacity, reflects variations in how Meftal is dispersed throughout the body, impacted by factors like age, body weight, and underlying medical conditions. Hepatic metabolism, a critical aspect mediated by cytochrome P450 enzymes, particularly CYP2C9, introduces significant variability, with genetic polymorphisms contributing to diverse rates of Meftal metabolism among individuals. Renal excretion, central to Meftal elimination, is subject to variability influenced by factors like age, pre-existing renal conditions, and co-administered drugs affecting renal clearance. Drug interactions, especially those affecting cytochrome P450 enzymes, can further alter Meftal metabolism, potentially influencing its efficacy and safety. Genetic polymorphisms in drug-metabolizing enzymes, environmental factors such as smoking, and the presence of underlying diseases further contribute to the intricate landscape of pharmacokinetic variability. Age-related changes and gender-specific considerations underscore the need for a nuanced approach to Meftal dosing, recognizing the impact of these factors on drug absorption, distribution, metabolism, and excretion in shaping individual responses to Meftal therapy [37].

5.4 Renal function

People who already have kidney problems such as chronic kidney disease, may respond differently to Meftal. Their kidneys may not be able to get rid of Meftal and its breakdown products as quickly as normal kidneys, leading to higher levels of the drug in the body. This can increase the chance of side effects or complications from Meftal. Therefore, people with kidney problems may need to take lower doses or less frequently of Meftal. They also need to check their kidney function regularly by doing blood tests that measure creatinine and GFR levels. These tests help the doctor adjust the Meftal dose according to the patient's kidney function. Patients should also drink enough water and report any symptoms of kidney damage, such as less urine or swelling in the legs, to their doctor as soon as possible. This helps prevent further harm to the kidneys and ensure safe and effective use of Meftal[38].

5.5 Cardiovascular Risk

Meftal can be a useful medicine for relieving pain and inflammation but it can also pose a risk to the heart and blood vessels. To reduce this risk, doctors should prescribe Meftal for the shortest possible time and at the lowest effective dose. They should also check the patient's heart health and other risk factors before starting Meftal. Patients who have a high risk of heart problems, such as those who have had a heart attack or stroke, may need a different painkiller or extra monitoring. Patients should be informed about the possible signs of heart trouble, such as chest pain, shortness of breath, or weakness, and seek medical help if they notice any of these symptoms. It is also important for doctors to work together with other specialists, such as cardiologists and rheumatologists, to provide the best care for patients who need Meftal and have heart conditions. This way, patients can benefit from Meftal without compromising their cardiovascular health [39].

6. RISKS AND BENEFITS IN SPECIAL POPULATIONS

Meftal, containing the active ingredient mefenamic acid, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used for pain relief and inflammation While it provides therapeutic benefits in various conditions, it is essential to consider potential risks and benefits, especially in special populations. In pregnant women, Meftal may pose risks to the developing fetus, particularly during the third trimester, and should be used cautiously under medical supervision. Breastfeeding women should also exercise caution, as mefenamic acid can be excreted in breast milk [40]. In elderly individuals, Meftal may increase the risk of gastrointestinal bleeding and cardiovascular events, warranting careful monitoring and dose adjustments. Individuals with a history of gastrointestinal ulcers, cardiovascular disease, or renal impairment may be more susceptible to adverse effects. The benefits of Meftal lie in its effectiveness in managing pain and inflammation; however, its use should be tailored to the specific needs and medical history of each patient, with close attention to potential risks in special populations. Consultation with a healthcare professional is crucial to weigh the risks and benefits in individual cases [41].

Table 1: The risks and benefits of Meftal in special populations

Special Populations	Benefits of Meftal	Risks of Meftal
Pregnant Women	Pain and inflammation relief	Potential harm to the fetus, especially in the third trimester. Use under medical supervision, consider alternatives.
Breastfeeding Woman	Effective pain management	Excretion in breast milk; caution advised, assess risk-benefit with a healthcare professional before prescribing.
Elderly Individuals	Effective pain management	Increased risk of gastrointestinal bleeding and cardiovascular events. Monitor closely, and consider dose adjustments.
Patients with Gastrointestinal Ulcers	Alleviation of pain and inflammation	Elevated risk of gastrointestinal bleeding; caution necessary. Explore alternative medications or gastroprotective agents.
Patients with Cardiovascular Disease	Anti-inflammatory and analgesic benefits	Increased risk of cardiovascular events; close monitoring recommended. Explore alternative pain management strategies.
Patients with Renal Impairment	Effective pain relief	Potential exacerbation of renal dysfunction; monitor closely, consider dose adjustments in those with pre-existing impairment.
Allergic Reactions	Pain and inflammation relief	Allergic reactions such as skin rash, itching, swelling; discontinue use if observed and seek medical attention.
Gastrointestinal Effects	Pain relief and anti-inflammatory effects	Risk of ulcers, bleeding, and perforation; increased in elderly; caution in those with a history of gastrointestinal issues.
Renal Effects	Pain relief	Potential for renal impairment or failure; caution in those with pre-existing renal conditions.
Liver Effects	Pain and inflammation relief	Rare cases of liver damage; monitor liver function and seek medical attention if symptoms of liver dysfunction appear.

7. FUTURE DIRECTIONS AND EMERGING TRENDS

Ongoing research in Meftal (mefenamic acid) is exploring potential therapeutic innovations and emerging trends to optimize its applications in pain management and anti-inflammatory treatment. Investigative efforts may delve into novel drug formulations and delivery systems, aiming to enhance pharmacokinetics and improve patient compliance. The exploration of combination therapies, involving the synergistic use of Meftal with other medications or therapeutic agents, may provide avenues to enhance efficacy or mitigate potential side effects. The advent of precision medicine approaches is likely to influence the tailoring of Meftal treatment to individual patients, considering genetic factors, patient characteristics, and specific disease markers. Deeper insights into Meftal's molecular mechanisms of action may pave the way for more targeted and effective therapies. Researchers may also seek to expand Meftal's therapeutic applications by exploring its efficacy in treating conditions beyond its current indications. The ongoing quest for a comprehensive understanding of Meftal's safety profile, especially in specific populations, may lead to strategies aimed at minimizing risks and improving patient safety. Additionally, the development of biomarkers associated with Meftal responsiveness or susceptibility to side effects could contribute to more personalized and targeted use of this NSAID. Overall, research in Meftal is dynamic and continuously evolving, with a focus on optimizing its therapeutic benefits while ensuring patient safety and efficacy.

8. CONCLUSION

Meftal, a nonsteroidal anti-inflammatory drug containing mefenamic acid is a widely used medication for pain relief and inflammation management. However, its use is associated with potential risks and benefits, especially in special populations such as pregnant and breastfeeding women, elderly individuals, and patients with pre-existing medical conditions. The pharmacokinetics and pharmacodynamics of Meftal are influenced by various factors such as genetic polymorphisms, drug interactions, and renal and hepatic function. Therefore, a comprehensive understanding of Meftal's mechanism of action, metabolism, side effects, and complications is essential for optimizing its therapeutic outcomes and ensuring patient safety. Ongoing research in Meftal is exploring novel formulations, delivery systems, combination therapies, and precision medicine approaches to enhance its efficacy and minimize its adverse effects. Meftal remains a valuable option for pain and inflammation treatment but its use requires careful consideration of individual variability and risk-benefit assessment.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable

CONSENT FOR PUBLICATION

Not applicable

AVAILABILITY OF DATA AND MATERIAL

Not applicable

COMPETING INTERESTS

Not applicable

FUNDING

Not applicable

ACKNOWLEDGEMENTS

NA

REFERENCES

1. Al-Ameer, L., K.K. Hashim, and D.N. Taha, Determination of mefenamic acid in aqueous solutions using merging zone-continuous flow injection. Water Practice & Technology, 2022. 17(9): p. 1881-1892.
2. Rajat, S., et al., An insight of non-steroidal anti-inflammatory drug mefenamic acid: A review. GSC Biological and Pharmaceutical Sciences, 2019. 7(2): p. -.
3. Dominguini, D., et al., Mitochondrial protective effects caused by the administration of mefenamic acid in sepsis. Journal of Neuroinflammation, 2022. 19(1): p. 1-13.
4. Behera, S.K., et al., DRESS syndrome: a detailed insight. Hospital Practice, 2018. 46(3): p. 152-162.
5. Cardones, A.R., Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clinics in Dermatology, 2020. 38(6): p. 702-711.
6. Klose, C., et al., Fenamates as TRP channel blockers: mefenamic acid selectively blocks TRPM3. Br J Pharmacol, 2011. 162(8): p. 1757-69.
7. Butt, A.R.S., et al., Synthesis and structure-activity relationship of tyrosinase inhibiting novel bi-heterocyclic acetamides: Mechanistic insights through enzyme inhibition, kinetics and computational studies. Bioorganic chemistry, 2019. 86: p. 459-472.

8. Garg, P. and M.C. Sanguinetti, Structure-activity relationship of fenamates as Slo2.1 channel activators. Mol Pharmacol, 2012. 82(5): p. 795-802.
9. Cimolai, N., The potential and promise of mefenamic acid. Expert review of clinical pharmacology, 2013. 6(3): p. 289-305.
10. Dogra, A., et al., Mefenamic Acid Loaded and TPGS Stabilized Mucoadhesive Nanoemulsion for the Treatment of Alzheimer's Disease: Development, Optimization, and Brain-Targeted Delivery via Olfactory Pathway. AAPS PharmSciTech, 2024. 25(1): p. 16.
11. Fikayuniar, L., et al., Content of Medicinal Chemicals in Traditional Herbal Medicine: A Systematic Literature Review. Eureka Herba Indonesia, 2024. 5(1): p. 394-399.
12. Somchit, M.N., et al., Mefenamic Acid induced nephrotoxicity: an animal model. Adv Pharm Bull, 2014. 4(4): p. 401-4.
13. Parthiban, U., Study of Cutaneous Manifestations in Children Presenting to Paediatric Emergency Department. 2017, Christian Medical College, Vellore.
14. Budoff, P.W., Use of mefenamic acid in the treatment of primary dysmenorrhea. JAMA, 1979. 241(25): p. 2713-2716.
15. Delgado, J., et al., Tolfenamic acid and mefenamic acid in the treatment of primary dysmenorrhoea. Pharmacology & Toxicology, 1994. 75: p. 89-91.
16. Bonnar, J. and B.L. Sheppard, Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. Bmj, 1996. 313(7057): p. 579-582.
17. van Eijkeren, M.A., et al., Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. American journal of obstetrics and gynecology, 1992. 166(5): p. 1419-1428.
18. Khan, H.Y., et al., Metal complexes of NSAIDs as potent anti-tumor chemotherapeutics: Mechanistic insights into cytotoxic activity via multiple pathways primarily by inhibition of COX-1 and COX-2 enzymes. Coordination Chemistry Reviews, 2022. 453: p. 214316.
19. G Perrone, M., et al., Selective COX-1 inhibition: A therapeutic target to be reconsidered. Current medicinal chemistry, 2010. 17(32): p. 3769-3805.
20. Useini, L., et al., Carboranyl analogues of mefenamic acid and their biological evaluation. ACS omega, 2022. 7(28): p. 24282-24291.
21. Rossokhin, A.V., et al., The mechanisms of potentiation and inhibition of GABAA receptors by non-steroidal anti-inflammatory drugs, mefenamic and niflumic acids. Neuropharmacology, 2019. 160: p. 107795.
22. Khansari, P.S. and R.F. Halliwell, Mechanisms underlying neuroprotection by the NSAID mefenamic acid in an experimental model of stroke. Frontiers in Neuroscience, 2019. 13: p. 64.
23. Bansal, K., S. Sharma, and M. Bajpai, Herbal Medicines-A Fruitful Approach to Periodic Illness Dysmenorrhoea: Evidence-based Review. Current Pharmaceutical Biotechnology, 2024. 25(2): p. 179-195.
24. Farkouh, A., et al., Interpreting the Benefit and Risk Data in Between-Drug Comparisons: Illustration of the Challenges Using the Example of Mefenamic Acid versus Ibuprofen. Pharmaceutics, 2022. 14(10): p. 2240.
25. Li, K.L. and A.L. Castillo, Formulation and evaluation of a mucoadhesive buccal tablet of mefenamic acid. Brazilian Journal of Pharmaceutical Sciences, 2020. 56: p. e18575.
26. Imai, T., et al., Enhancement of dissolution and absorption of mefenamic acid by egg albumin. J Pharm Sci, 1991. 80(5): p. 484-7.
27. Nurhikmah, W., Y.C. Sumirtapura, and J.S. Pamudji, Dissolution Profile of Mefenamic Acid Solid Dosage Forms in Two Compendial and Biorelevant (FaSSIF) Media. Sci Pharm, 2016. 84(1): p. 181-90.
28. Hamaguchi, T., et al., Bioavailability of mefenamic acid: influence of food and water intake. J Pharm Sci, 1986. 75(9): p. 891-3.
29. Vinnikova, A.V., et al., [Mefenaminic acid binding by blood plasma and organ homogenates]. Farmakol Toksikol, 1980. 43(2): p. 187-92.
30. Khansari, P.S. and R.F. Halliwell, Mechanisms Underlying Neuroprotection by the NSAID Mefenamic Acid in an Experimental Model of Stroke. Frontiers in Neuroscience, 2019. 13.
31. Anima, G., et al., Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor. Drug Metabolism and Disposition, 2011. 39(3): p. 510.
32. Ali, K.A., et al., Chapter 4 - Insight into the mechanism of steroidal and non-steroidal anti-inflammatory drugs, in How Synthetic Drugs Work, I. Kazmi, et al., Editors. 2023, Academic Press. p. 61-94.
33. Jarrar, Q.B., et al., Renal ultrastructural alterations induced by various preparations of mefenamic acid. Ultrastructural pathology, 2020. 44(1): p. 130-140.
34. Chen, C.-H., Genetic Variations and Polymorphisms of Metabolic Enzymes, in Xenobiotic Metabolic Enzymes: Bioactivation and Antioxidant Defense, C.-H. Chen, Editor. 2020, Springer International Publishing: Cham. p. 155-168.
35. Zhou, Y., et al., Global distribution of functionally important

CYP2C9 alleles and their inferred metabolic consequences. Human Genomics, 2023. 17(1): p. 15.

36. Daly, A.K., et al. Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. Journal of Personalized Medicine, 2018. 8, DOI: 10.3390/jpm8010001.
37. Valentovic, M., Mefenamic Acid, in xPharm: The Comprehensive Pharmacology Reference, S.J. Enna and D.B. Bylund, Editors. 2007, Elsevier: New York. p. 1-5.
38. Meftal Spas DS Tablet 10'S. Available from: https://www.netmeds.com/ prescriptions/meftal-spas-ds-tablet-10-s.
39. Cherumanalil, J.M., et al., Prescription pattern of non-steroidal anti-inflammatory drugs among patients admitted with fever in a tertiary hospital. International Journal of Basic & Clinical Pharmacology, 2023. 12(2): p. 167-172.
40. Meftal TX Tablet. Available from: https://www.1mg.com/drugs/meftal-tx-tablet-251028.
41. Kumar, M., D. Singh, and N. Bedi, Mefenamic acid-loaded solid SMEDDS: an innovative aspect for dose reduction and improved pharmacodynamic profile. Therapeutic Delivery, 2018. 10(1): p. 21-36.